Home
Project
Recruiting sites
Partners
Impact
Resources
Contact
News

Flyers of clinical sites

About us

The RECOMB consortium brings together a large number of clinical and research professionals from 16 European and 1 Israeli institutes with expertise in the management of primary immunodeficiencies, such as SCID.

Our mission

The ultimate aim of RECOMB is to create a treatment for the most common type of SCID, RAG1-SCID by performing phase 1 and phase 2 clinical trials using autologous haematopoietic stem cell‒based gene therapy.

Useful links

Learn more about Primary immunodeficiencies
Learn more about SCID
Learn more about Gene Therapy

This project has received funding from the European Union’s Horizon 2020 research and
innovation programme under grant agreement n° 755170’